Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early vs delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 Trial. Have a read: https://www.m3india.in/contents/journal/multicenter-open-label-extension-trial-to-evaluate-the-long-term-efficacy-and?utm_campaign=unset&utm_medium=share&utm_source=ref_wa